Search

Your search keyword '"Angrilli, Francesco"' showing total 370 results
Start Over Author "Angrilli, Francesco"
370 results on '"Angrilli, Francesco"'

1. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

2. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Author

Ferreri, Andrés J M, Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P, Schorb, Elisabeth, La Rosée, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire, Johnson, Peter, Linton, Kim M, Pukrop, Tobias, Sønderskov Gørløv, Jette, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W, Schmoll, Hans J, Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S, Finke, Jürgen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, and Illerhaus, Gerald

Published
2017
Full Text
View/download PDF

4. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

Author

Gentile, Massimo, Shanafelt, Tait D., Reda, Gianluigi, Mauro, Francesca Romana, Zirlik, Katja, Ciolli, Stefania, Laurenti, Luca, Del Principe, Maria Ilaria, Rossi, Davide, Di Renzo, Nicola, Molica, Stefano, Angrilli, Francesco, Coscia, Marta, Chiarenza, Annalisa, Giordano, Annamaria, Cutrona, Giovanna, Chaffee, Kari G., Parikh, Sameer A., Uccello, Giuseppina, Innocenti, Idanna, Tripepi, Giovanni, D’Arrigo, Graziella, Vigna, Ernesto, Recchia, Anna Grazia, Herishanu, Yair, Shvidel, Lev, Tadmor, Tamar, Cortelezzi, Agostino, Del Poeta, Giovanni, Gaidano, Gianluca, Di Raimondo, Francesco, Neri, Antonino, Ferrarini, Manlio, Foà, Robin, Polliack, Aaron, and Morabito, Fortunato

Published
2018
Full Text
View/download PDF

5. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro, Francesca R., Molica, Stefano, Laurenti, Luca, Cortelezzi, Agostino, Carella, Angelo M., Zaja, Francesco, Chiarenza, Annalisa, Angrilli, Francesco, Nobile, Francesco, Marasca, Roberto, Musolino, Caterina, Brugiatelli, Maura, Piciocchi, Alfonso, Vignetti, Marco, Fazi, Paola, Gentile, Giuseppe, De Propris, Maria S., Starza, Irene Della, Marinelli, Marilisa, Chiaretti, Sabina, Del Giudice, Ilaria, Nanni, Mauro, Albano, Francesco, Cuneo, Antonio, Guarini, Anna, and Foà, Robin

Published
2014
Full Text
View/download PDF

7. Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Author

Gobbi, Paolo G., Valentino, Francesco, Bassi, Emilio, Coriani, Chiara, Merli, Francesco, Bonfante, Valeria, Marchianò, Alfonso, Gallamini, Andrea, Bolis, Silvia, Stelitano, Caterina, Levis, Alessandro, Federico, Massimo, Angrilli, Francesco, Di Giulio, Giuseppe, and Corazza, Gino R.

Published
2011
Full Text
View/download PDF

8. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Molica, Stefano, Ilariucci, Fiorella, Mauro, Francesca R., Di Renzo, Nicola, Di Raimondo, Francesco, Vincelli, Iolanda, Todoerti, Katia, Matis, Serena, Musolino, Caterina, Fabris, Sonia, Lionetti, Marta, Levato, Luciano, Zupo, Simona, Angrilli, Francesco, Consoli, Ugo, Festini, Gianluca, Longo, Giuseppe, Cortelezzi, Agostino, Musto, Pellegrino, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2016
Full Text
View/download PDF

11. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Mosca, Laura, Matis, Serena, Fabris, Sonia, Lionetti, Marta, Ilariucci, Fiorella, Zupo, Simona, Musolino, Caterina, Levato, Luciano, Molica, Stefano, Di Raimondo, Francesco, Vincelli, Iolanda, Di Rienzo, Nicola, Pesce, Emanuela Anna, Angrilli, Francesco, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2014
Full Text
View/download PDF

13. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Fabris, Sonia, Pesce, Emanuela Anna, Baldini, Luca, Di Raimondo, Francesco, Musolino, Caterina, Di Tonno, Paolo, Di Renzo, Nicola, Molica, Stefano, Brugiatelli, Maura, Ilariucci, Fiorella, Zupo, Simona, Matis, Serena, Maura, Francesco, Vigna, Ernesto, Angrilli, Francesco, Recchia, Anna Grazia, Quarta, Giovanni, Iannitto, Emilio, Fragasso, Alberto, Musto, Pellegrino, Spriano, Mauro, Vincelli, Iolanda, Vallisa, Daniele, Cortelezzi, Agostino, Mauro, Francesca Romana, Foà, Robin, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2013
Full Text
View/download PDF

15. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia

Author

Fabris, Sonia, Mosca, Laura, Cutrona, Giovanna, Lionetti, Marta, Agnelli, Luca, Ciceri, Gabriella, Barbieri, Marzia, Maura, Francesco, Matis, Serena, Colombo, Monica, Gentile, Massimo, Recchia, Anna Grazia, Anna Pesce, Emanuela, Di Raimondo, Francesco, Musolino, Caterina, Gobbi, Marco, Di Renzo, Nicola, Mauro, Francesca Romana, Brugiatelli, Maura, Ilariucci, Fiorella, Lipari, Maria Grazia, Angrilli, Francesco, Consoli, Ugo, Fragasso, Alberto, Molica, Stefano, Festini, Gianluca, Vincelli, Iolanda, Cortelezzi, Agostino, Federico, Massimo, Morabito, Fortunato, Ferrarini, Manlio, and Neri, Antonino

Published
2013
Full Text
View/download PDF

16. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi

Author

Merli, Francesco, Luminari, Stefano, Ilariucci, Fiorella, Petrini, Mario, Visco, Carlo, Ambrosetti, Achille, Stelitano, Caterina, Caracciolo, Francesco, Di Renzo, Nicola, Angrilli, Francesco, Carella, Angelo M., Capodanno, Isabella, Barbolini, Elisa, Galimberti, Sara, and Federico, Massimo

Published
2012
Full Text
View/download PDF

17. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

Author

Massaro, Fulvio, primary, Stepanishyna, Yana, additional, Manni, Martina, additional, Luminari, Stefano, additional, Galimberti, Sara, additional, Marcheselli, Luigi, additional, Visco, Carlo, additional, Tecchio, Cristina, additional, Stelitano, Caterina, additional, Angrilli, Francesco, additional, Petrini, Mario, additional, Merli, Francesco, additional, and Federico, Massimo, additional

Published
2020
Full Text
View/download PDF

18. Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Author

Spina, Michele, primary, Merli, Francesco, primary, Puccini, Benedetta, primary, Cavallo, Federica, primary, Cabras, Maria Giuseppina, primary, Fabbri, Alberto, primary, Angrilli, Francesco, primary, Zilioli, Vittorio Ruggero, primary, Marino, Dario, primary, Balzarotti, Monica, primary, Ladetto, Marco, primary, Cox, M. Christina Christina, primary, Petrucci, Luigi, primary, Arcari, Annalisa, primary, Gini, Guido, primary, Chiappella, Annalisa, primary, Hohaus, Stefan, primary, Musuraca, Gerardo, primary, Merli, Michele, primary, Sartori, Roberto, primary, Nassi, Luca, primary, Tani, Monica, primary, Re, Francesca, primary, Flenghi, Leonardo, primary, Molinari, Anna Lia, primary, Kovalchuk, Sofia, primary, Bottelli, Chiara, primary, Ferrero, Simone, primary, Dessì, Daniela, primary, Cencini, Emanuele, primary, Pennese, Elsa, primary, Tabanelli, Valentina, primary, Marcheselli, Luigi, primary, Mammi, Caterina, primary, Luminari, Stefano, primary, and Tucci, Alessandra, primary

Published
2019
Full Text
View/download PDF

20. Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial

Author

Iannitto, Emilio, Minardi, Viviana, Gobbi, Paolo G., Calvaruso, Giuseppina, Tripodo, Claudio, Marcheselli, Luigi, Luminari, Stefano, Merli, Francesco, Baldini, Luca, Stelitano, Caterina, Callea, Vincenzo, Petrini, Mario, Angrilli, Francesco, Quarta, Giovanni, Vallisa, Daniele, Molica, Stefano, Liardo, Eliana, Polimeno, Giuseppe, Brugiatelli, Maura, and Federico, Massimo

Published
2009

23. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

Author

Bruna, Riccardo, primary, Benedetti, Fabio, additional, Boccomini, Carola, additional, Patti, Caterina, additional, Barbui, Anna Maria, additional, Pulsoni, Alessandro, additional, Musso, Maurizio, additional, Liberati, Anna Marina, additional, Gini, Guido, additional, Castellino, Claudia, additional, Rossini, Fausto, additional, Ciceri, Fabio, additional, Rota-Scalabrini, Delia, additional, Stelitano, Caterina, additional, Di Raimondo, Francesco, additional, Tucci, Alessandra, additional, Devizzi, Liliana, additional, Zoli, Valerio, additional, Zallio, Francesco, additional, Narni, Franco, additional, Dondi, Alessandra, additional, Parvis, Guido, additional, Semenzato, Gianpietro, additional, Lanza, Francesco, additional, Perrone, Tommasina, additional, Angrilli, Francesco, additional, Billio, Atto, additional, Gueli, Angela, additional, Mantoan, Barbara, additional, Rambaldi, Alessandro, additional, Gianni, Alessandro Massimo, additional, Corradini, Paolo, additional, Passera, Roberto, additional, Ladetto, Marco, additional, and Tarella, Corrado, additional

Published
2019
Full Text
View/download PDF

24. Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi

Author

Luminari, Stefano, primary, Marcheselli, Luigi, additional, Defrancesco, Irene, additional, Rattotti, Sara, additional, Cesaretti, Marina, additional, Frigeni, Marco, additional, Sciarra, Roberta, additional, Cavallo, Federica, additional, Deodato, Marina, additional, Cabras, Maria Giuseppina, additional, Merli, Michele, additional, Ferrari, Angela, additional, Re, Francesca, additional, Spina, Michele, additional, Cencini, Emanuele, additional, Annibali, Ombretta, additional, Pulsoni, Alessandro, additional, Delamain, Marcia Torresan, additional, Mannina, Donato, additional, Gaidano, Gianluca, additional, Stelitano, Caterina, additional, Ferrari, Daris, additional, Visco, Carlo, additional, Angrilli, Francesco, additional, Tarantino, Vittoria, additional, and Arcaini, Luca, additional

Published
2018
Full Text
View/download PDF

25. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.

Author

Massaro, Fulvio, Stepanishyna, Yana, Manni, Martina, Luminari, Stefano, Galimberti, Sara, Marcheselli, Luigi, Visco, Carlo, Tecchio, Cristina, Stelitano, Caterina, Angrilli, Francesco, Petrini, Mario, Merli, Francesco, and Federico, Massimo

Subjects
RITUXIMAB, METHOTREXATE, CYTARABINE, STEM cell transplantation, LYMPHOPROLIFERATIVE disorders, MANTLE cell lymphoma, CASTLEMAN'S disease
Abstract

Summary: Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R‐HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R‐CVAD) alternating with high‐dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow‐up of 10·5 years, we reported 10‐year progression‐free and overall survival rates of 35% and 61% respectively, with a 10‐years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD‐AM as a frontline regimen for younger patients (≤65 years). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Nonpeghylated liposomal doxorubicin combination regimen (R‐COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity.

Author

Rigacci, Luigi, Annibali, Ombretta, Kovalchuk, Sofya, Bonifacio, Elisabetta, Pregnolato, Francesca, Angrilli, Francesco, Vitolo, Umberto, Pozzi, Samantha, Broggi, Serena, Luminari, Stefano, Merli, Francesco, Spina, Michele, Bolis, Silvia, Margiotta‐Casaluci, Gloria, Scalzulli, Rosario, Cox, Christina, Mamusa, Angela Maria, Santoro, Armando, Zinzani, Pier Luigi, and Ferrari, Samantha

Subjects
CORONARY disease, PROGRESSION-free survival, LYMPHOMAS, PULMONARY edema, HEART diseases
Abstract

Doxorubicin is the most effective single agent in the treatment of non‐Hodgkin's lymphoma (NHL). Its use is limited because of the cardiac toxicity primarily in elderly patients (pts) and in pts with history of cardiac disease. Liposomal doxorubicin has been proven to reduce cardiotoxicity. The aim of this retrospective study was the use of nonpeghylated liposomal doxorubicin (NPLD) in term of efficacy, response rate and incidence of cardiac events. We retrospectively collected the experience of 33 Hematological Italian Centers in using NPLD. Nine hundred and forty‐six consecutive pts treated with R‐COMP (doxorubicin was substituted with NPLD, Myocet) were collected. Median age was 74 years, the reasons for use of NPLD were: age (466 pts), cardiac disease (298 pts), uncontrolled hypertension (126 pts), other reasons (56 pts). According to clinicians' evaluation, 49.9% of pts would not have used standard doxorubicin for different situations (age, cardiomyopathy, previous use of doxorubicin, and uncontrolled hypertension). Overall 687 pts (72.6%) obtained a complete remission (CR). About 5% (n = 51) of subjects developed major cardiotoxic events including heart failure (N = 31), ischemic heart disease (N = 16), acute heart attack (N = 3), and acute pulmonary oedema (N = 1). After a median follow‐up of 32 months, 651 pts were alive and the overall survival (OS) was 72%. After a median observation period of 23 months disease free survival (DFS) was 58%. Either in univariate or in multivariate analysis OS and DFS were not significantly affected by age or cardiac disease. Our findings strongly support that including R‐COMP is effective and safe when the population is at high risk of cardiac events and negatively selected. Moreover, the use of this NPLD permitted that about half of our population had the opportunity to receive the best available treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

27. Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment

Author

Gentile, Massimo, primary, Shanafelt, Tait D., additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Rossi, Davide, additional, Laurenti, Luca, additional, Del Principe, Maria Ilaria, additional, Cutrona, Giovanna, additional, Angeletti, Ilaria, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Chiarenza, Annalisa, additional, Molica, Stefano, additional, Ciolli, Stefania, additional, Goldschmidt, Neta, additional, Angrilli, Francesco, additional, Giordano, Annamaria, additional, Rago, Angela, additional, Bairey, Osnat, additional, Tripepi, Giovanni, additional, Chaffee, Kari G., additional, Sameer, Parikh A., additional, Vigna, Ernesto, additional, Zirlik, Katja, additional, Shvidel, Lev, additional, Innocenti, Idanna, additional, Recchia, Anna Grazia, additional, Di Raimondo, Francesco, additional, Del Poeta, Giovanni, additional, Cortelezzi, Agostino, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Gaidano, Gianluca, additional, Kay, Neil E., additional, Polliack, Aaron, additional, Foà, Robin, additional, and Morabito, Fortunato, additional

Published
2018
Full Text
View/download PDF

28. Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases

Author

Morabito, Fortunato, primary, Shanafelt, Tait D, additional, Gentile, Massimo, additional, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Rossi, Davide, additional, Di Renzo, Nicola, additional, Molica, Stefano, additional, Angrilli, Francesco, additional, Chiarenza, Annalisa, additional, Cutrona, Giovanna, additional, Chaffee, Kari G., additional, Parikh, Sameer A., additional, Tripepi, Giovanni, additional, D'Arrigo, Graziella, additional, Vigna, Ernesto, additional, Recchia, Anna Grazia, additional, Cortelezzi, Agostino, additional, Gaidano, Gianluca, additional, Di Raimondo, Francesco, additional, Fais, Franco, additional, Foà, Robin, additional, Neri, Antonino, additional, and Ferrarini, Manlio, additional

Published
2018
Full Text
View/download PDF

29. MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients

Author

Ambrosio, Maria R., primary, Lazzi, Stefano, additional, Bello, Giuseppe Lo, additional, Santi, Raffaella, additional, Porro, Leonardo Del, additional, de Santi, Maria M., additional, Guazzo, Raffaella, additional, Mundo, Lucia, additional, Rigacci, Luigi, additional, Kovalchuck, Sofia, additional, Onyango, Noel, additional, Fabbri, Alberto, additional, Cencini, Emanuele, additional, Zinzani, Pier Luigi, additional, Zaja, Francesco, additional, Angrilli, Francesco, additional, Stelitano, Caterina, additional, Cabras, Maria G., additional, Spataro, Giuseppe, additional, Bob, Roshanak, additional, Menter, Thomas, additional, Granai, Massimo, additional, Cevenini, Gabriele, additional, Naresh, Kikkeri N., additional, Stein, Harald, additional, Sabattini, Elena, additional, and Leoncini, Lorenzo, additional

Published
2018
Full Text
View/download PDF

30. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma

Author

Luminari, Stefano, primary, Ferrari, Angela, additional, Manni, Martina, additional, Dondi, Alessandra, additional, Chiarenza, Annalisa, additional, Merli, Francesco, additional, Rusconi, Chiara, additional, Tarantino, Vittoria, additional, Tucci, Alessandra, additional, Vitolo, Umberto, additional, Kovalchuk, Sofia, additional, Angelucci, Emanuele, additional, Pulsoni, Alessandro, additional, Arcaini, Luca, additional, Angrilli, Francesco, additional, Gaidano, Gianluca, additional, Stelitano, Caterina, additional, Bertoldero, Giovanni, additional, Cascavilla, Nicola, additional, Salvi, Flavia, additional, Ferreri, Andrés J.M., additional, Vallisa, Daniele, additional, Marcheselli, Luigi, additional, and Federico, Massimo, additional

Published
2018
Full Text
View/download PDF

32. Updated 13 Yr Follow-Up of the GITMO-IIL Trial Comparing Upfront R-HDS with Autograft vs. CHOP-R in High-Risk Follicular Lymphoma: Prolonged Survival in Both Arms and a High Rate of Long-Term Disease Free Survivors

Author

Bruna, Riccardo, primary, Benedetti, Fabio, additional, Boccomini, Carola, additional, Patti, Caterina, additional, Barbui, Anna Maria, additional, Pulsoni, Alessandro, additional, Musso, Maurizio, additional, Liberati, Anna Marina, additional, Gini, Guido, additional, Castellino, Claudia, additional, Rossini, Fausto, additional, Ciceri, Fabio, additional, Rota-Scalabrini, Delia, additional, Stelitano, Caterina, additional, Di Raimondo, Francesco, additional, Tucci, Alessandra, additional, Devizzi, Liliana, additional, Zoli, Valerio, additional, Zallio, Francesco, additional, Narni, Franco, additional, Dondi, Alessandra, additional, Parvis, Guido, additional, Semenzato, Gianpietro, additional, Lanza, Francesco, additional, Perrone, Tommasina, additional, Angrilli, Francesco, additional, Billio, Atto, additional, Gueli, Angela, additional, Mantoan, Barbara, additional, Rambaldi, Alessandro, additional, Gianni, Alessandro Massimo, additional, Corradini, Paolo, additional, Passera, Roberto, additional, Ladetto, Marco, additional, and Tarella, Corrado, additional

Published
2018
Full Text
View/download PDF

33. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Author

Ferreri, Andres J. M., Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P., Schorb, Elisabeth, La Rosee, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire, Johnson, Peter, Linton, Kim M., Pukrop, Tobias, Gorlov, Jette Sonderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W., Schmoll, Hans J., Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Juergen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, Illerhaus, Gerald, Ferreri, Andres J. M., Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P., Schorb, Elisabeth, La Rosee, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire, Johnson, Peter, Linton, Kim M., Pukrop, Tobias, Gorlov, Jette Sonderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W., Schmoll, Hans J., Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Juergen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, and Illerhaus, Gerald

Abstract

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy. Methods HIV-negative patients (aged 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group performance status of 0-3 were randomly assigned to receive four courses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice daily on days 2 and 3 (group A); or the same combination plus two doses of rituximab 375 mg/m(2) on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three groups repeating treatment every 3 weeks. Patients with responsive or stable disease after induction treatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatrogenic side-effects, were eligible for the second randomisation between WBRT (photons of 4-10 MeV; five fractions per week; fraction size 180 cGy; started within 4 weeks from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m(2) on day -6, and thiotepa 5 mg/kg every 12 h on days -5 and -4, followed by reinfusion of autologous peripheral blood stem cells; group E). A permuted block randomised design was adopted for both randomisa

Published
2017

34. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients

Author

Molica, Stefano, Shanafelt, Tait D., Giannarelli, Diana, Gentile, Massimo, Mirabelli, Rosanna, Cutrona, Giovanna, Levato, Luciano, Di Renzo, Nicola, Di Raimondo, Francesco, Musolino, Caterina, Angrilli, Francesco, Famà, Angelo, Recchia, Anna Grazia, Chaffee, Kari G., Neri, Antonino, Kay, Neil E., Ferrarini, Manlio, and Morabito, Fortunato

Subjects
Adult, Male, leukemia, Hematology, Middle Aged, leukemia, Hematology, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Article, Time-to-Treatment, Cohort Studies, Italy, immune system diseases, Predictive Value of Tests, hemic and lymphatic diseases, Humans, Female, Prospective Studies, neoplasms, Aged
Abstract

The chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) combines 5 parameters (age, clinical stage, TP53 status [normal vs. del(17p) and/or TP53 mutation], IGHV mutational status, serum β2-microglobulin) to predict survival and time-to-first-treatment (TTFT) in CLL patients. We performed an observational study in 337 prospectively collected, Binet stage A patients to validate the ability of the CLL-IPI to predict TTFT in an independent cohort of early stage CLL patients. The CLL-IPI score stratified Binet stage A patients into three subgroups with different outcome. Since the CLL-IPI was originally developed to predict survival, we next investigated the optimal cut-off score to predict TTFT in Binet stage A patients. Recursive partitioning analysis identified three subsets with scores of 0 (n = 139), 1 (n = 90), and ≥ 2(n = 108). The probability of remaining free from therapy 5 years after diagnosis was 85%, 67% and 46% in these three categories (P 0.0001.; C-statistic:c = 0.72; 95% CI:0.58-0.81). This optimized CLL-IPI scoring for TTFT was subsequently validated in an independent cohort of Binet A patients from the Mayo Clinic (n = 525). The ability of either original or optimized CLL-IPI to predict TTFT was equivalent to other prognostic models specifically designed for this endpoint (2011 MDACC score and O-CLL1 score). Although originally developed to predict suvival, the CLL-IPI is useful for predicting TTFT in early stage CLL patients. Am. J. Hematol. 91:1090-1095, 2016. © 2016 Wiley Periodicals, Inc.

Published
2016

35. Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study

Author

Ricciuti, Giuseppina, primary, Finolezzi, Erica, additional, Luciani, Stefania, additional, Ranucci, Elena, additional, Federico, Massimo, additional, Di Nicola, Marta, additional, Zecca, Isaia Antonio Luca, additional, and Angrilli, Francesco, additional

Published
2017
Full Text
View/download PDF

36. Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Author

Ferreri, Andrés J.M., primary, Cwynarski, Kate, additional, Pulczynski, Elisa Jacobsen, additional, Fox, Christopher P., additional, Schorb, Elisabeth, additional, La Rosée, Paul, additional, Binder, Mascha, additional, Fabbri, Alberto, additional, Torri, Valter, additional, Minacapelli, Eleonora, additional, Falautano, Monica, additional, Ilariucci, Fiorella, additional, Ambrosetti, Achille, additional, Röth, Alexander, additional, Hemmaway, Claire Jane, additional, Johnson, Peter M, additional, Linton, Kim, additional, Pukrop, Tobias, additional, Sonderskov Gorlov, Jette, additional, Balzarotti, Monica, additional, Hess, Georg, additional, Keller, Ulrich, additional, Stilgenbauer, Stephan, additional, Panse, Jens P., additional, Tucci, Alessandra, additional, Orsucci, Lorella, additional, Pisani, Francesco, additional, Levis, Alessandro, additional, Krause, Stefan W., additional, Schmoll, Hans-Joachim, additional, Hertenstein, Bernd, additional, Rummel, Mathias, additional, Smith, Jeffery, additional, Pfreundschuh, Michael, additional, Cabras, Giuseppina, additional, Angrilli, Francesco, additional, Ponzoni, Maurilio, additional, Deckert, Martina, additional, Politi, Letterio S., additional, Finke, Jurgen, additional, Reni, Michele, additional, Cavalli, Franco, additional, Zucca, Emanuele, additional, and Illerhaus, Gerald, additional

Published
2016
Full Text
View/download PDF

37. Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Author

Ferreri, Andres J. M., Cwynarski, Kate, Pulczynski, Elisa Jacobsen, Fox, Christopher P., Schorb, Elisabeth, La Rosee, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire Jane, Johnson, Peter M., Linton, Kim, Pukrop, Tobias, Gorlov, Jette Sonderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens P., Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W., Schmoll, Hans-Joachim, Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Jurgen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, Illerhaus, Gerald, Ferreri, Andres J. M., Cwynarski, Kate, Pulczynski, Elisa Jacobsen, Fox, Christopher P., Schorb, Elisabeth, La Rosee, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire Jane, Johnson, Peter M., Linton, Kim, Pukrop, Tobias, Gorlov, Jette Sonderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens P., Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W., Schmoll, Hans-Joachim, Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Jurgen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, and Illerhaus, Gerald

Published
2016

38. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Author

Mauro Francesca, R, Molica, Stefano, Laurenti, Luca, Cortelezzi, Agostino, Carella Angelo, M., Zaja, Francesco, Chiarenza, Annalisa, Angrilli, Francesco, Nobile, Francesco, Marasca, Roberto, Musolino, Caterina, Brugiatelli, Maura, Piciocchi, Alfonso, Vignetti, Marco, Fazi, Paola, Gentile, Giuseppe, De Propris Maria, S., Starza Irene Della, Marinelli, Marilisa, Chiaretti, Sabina, Del Giudice Ilaria, Nanni, Mauro, Albano, Francesco, Cuneo, Antonio, Guarini, Anna, Foà, Robin, per il gruppo GIMEMA Working Party Chronic Lymph, Massaia, M., Mauro, Fr, Molica, S, Laurenti, L, Cortelezzi, A, Carella, Am, Zaja, Francesco, Chiarenza, A, Angrilli, F, Nobile, F, Marasca, R, Musolino, C, Brugiatelli, M, Piciocchi, A, Vignetti, M, Fazi, P, Gentile, G, De Propris, M, Della Starza, I, Marinelli, M, Chiaretti, S, Del Giudice, I, Nanni, M, Albano, F, Cuneo, A, Guarini, A, and Foà, R.

Subjects
Oncology, Male, Cancer Research, medicine.medical_treatment, Chronic lymphocytic leukemia, THERAPY, Fludarabine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Chronic, Alemtuzumab, Humanized, Vidarabine, Neoadjuvant therapy, Hematology, Leukemia, STEM CELL TRANSPLANTATION, Medicine (all), Middle Aged, Lymphocytic, Neoadjuvant Therapy, Treatment Outcome, Female, PHASE-II TRIAL, medicine.drug, EXPRESSION, Adult, medicine.medical_specialty, Young, Biology, CLL, Antibodies, Monoclonal, Humanized, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Survival Analysis, Antibodies, Chronic lymphocytic leukemia, CLL, Young, Biology, Fludarabine, Alemtuzumab, STEM CELL TRANSPLANTATION, PHASE-II TRIAL, TERM FOLLOW UP, SUBCUTANEOUS ALEMTUZUMAB, DISEASE PROGRESSION, POOR PROGNOSIS, FREE SURVIVAL, EXPRESSION, RITUXIMAB, THERAPY, Internal medicine, SUBCUTANEOUS ALEMTUZUMAB, RITUXIMAB, Survival analysis, business.industry, DISEASE PROGRESSION, B-Cell, medicine.disease, Transplantation, Settore MED/15 - MALATTIE DEL SANGUE, POOR PROGNOSIS, Immunology, TERM FOLLOW UP, FREE SURVIVAL, business
Abstract

In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Published
2014

39. Comet 67P/Churyumov-Gerasimenko: First science results by Rosetta/OSIRIS

Author

Thomas, Nicolas, Sierks, Holger, Barbieri, Cesare, Lamy, Philippe, Rodrigo, Rafael, Koschny, Detlef, Rickman, Hans, Agarwal, Jessica, A Hearn, Michael, Angrilli, Francesco, Barucci, Antonella, Bertaux, Jean-Loup, Bertini, Ivano, Besse, Sebastien, Bodewits, Dennis, Capanna, Claire, Cremonese, Gabriele, Da Deppo, Vania, Davidsson, Björn, Debei, Stefano, Cecco, Mariolino, Ferri, Francesca, Fornasier, Sonia, marco fulle, Gaskell, Robert, Groussin, Olivier, Güttler, Carsten, Gutierrez, Pedroj, Hviid, Stubbe, Ip, Wing-Huen, Jorda, Laurent, Keller, Horst Uwe, Knollenberg, Jörg, Kramm, Rainer, Kührt, Ekkehard, Küppers, Michael, Laforgia, Fiorangela, Lara, Luisa, Lazzarin, Monica, Leyrat, Cedric, Lopez Moreno, Jose Juan, Lowry, Stephen, Magrin, Sara, Marchi, Simone, Marzari, Francesco, Michalik, Harald, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Pajola, Maurizio, Sabau, Lola, Snodgrass, Colin, Tubiana, Cecilia, Vincent, Jean-Baptiste, and Wenzel, Peter

Abstract

ESA's Rosetta mission arrived on August 6, 2014, at target comet 67P/Churyumov-Gerasimenko after 10 years of cruise. OSIRIS (Optical, Spectroscopic, and Infrared Remote Imaging System) is the scientific imaging system onboard Rosetta. It comprises a Narrow Angle Camera (NAC) for nucleus surface and dust studies and a Wide Angle Camera (WAC) for the wide field coma investigations.We present the first science results achieved by OSIRIS from the arrival at the comet throughout the mapping phase. The overview will cover surface morphology and activity of the nucleus as seen in gas, dust, and local jets.AcknowledgementsOSIRIS was built by a consortium led by the Max-Planck-Institut für Sonnensystemforschung, Göttingen, Germany, in collaboration with CISAS, University of Padova, Italy, the Laboratoire d'Astrophysique de Marseille, France, the Instituto de Astrofísica de Andalucia, CSIC, Granada, Spain, the Scientific Support Office of the European Space Agency, Noordwijk, The Netherlands, the Instituto Nacional de Técnica Aeroespacial, Madrid, Spain, the Universidad Politéchnica de Madrid, Spain, the Department of Physics and Astronomy of Uppsala University, Sweden, and the Institut für Datentechnik und Kommunikationsnetze der Technischen Universität Braunschweig, Germany. The support of the national funding agencies of Germany (DLR), France (CNES), Italy (ASI), Spain (MEC), Sweden (SNSB), and the ESA Technical Directorate is gratefully acknowledged. We thank the Rosetta Science Ground Segment at ESAC, the Rosetta Mission Operations Centre at ESOC and the Rosetta Project at ESTEC for their outstanding work enabling the science return of the Rosetta Mission.

Published
2014

41. Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials

Author

Gentile, Massimo, primary, Zirlik, Katja, additional, Ciolli, Stefania, additional, Mauro, Francesca R., additional, Di Renzo, Nicola, additional, Mastrullo, Lucia, additional, Angrilli, Francesco, additional, Molica, Stefano, additional, Tripepi, Giovanni, additional, Giordano, Annamaria, additional, Di Raimondo, Francesco, additional, Selleri, Carmine, additional, Coscia, Marta, additional, Musso, Maurizio, additional, Orsucci, Lorella, additional, Mannina, Donato, additional, Rago, Angela, additional, Giannotta, Angela, additional, Ferrara, Felicetto, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Tadmor, Tamar, additional, Scortechini, Ilaria, additional, Ilariucci, Fiorella, additional, Murru, Roberta, additional, Guarini, Attilio, additional, Musuraca, Gerardo, additional, Mineo, Giuseppe, additional, Vincelli, Iolanda, additional, Arcari, Annalisa, additional, Tarantini, Giuseppe, additional, Caparrotti, Giuseppe, additional, Chiarenza, Annalisa, additional, Levato, Luciano, additional, Villa, Maria Rosaria, additional, De Paolis, Maria Rosaria, additional, Zinzani, Pier Luigi, additional, Polliack, Aaron, additional, and Morabito, Fortunato, additional

Published
2016
Full Text
View/download PDF

42. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi

Author

Merli, Francesco, primary, Luminari, Stefano, additional, Gobbi, Paolo G., additional, Cascavilla, Nicola, additional, Mammi, Caterina, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Musso, Maurizio, additional, Baldini, Luca, additional, Galimberti, Sara, additional, Angrilli, Francesco, additional, Polimeno, Giuseppe, additional, Scalzulli, Potito Rosario, additional, Ferrari, Angela, additional, Marcheselli, Luigi, additional, and Federico, Massimo, additional

Published
2016
Full Text
View/download PDF

43. Benda-BEAM High-Dose Therapy Prior to Auto-SCT is Effective in Resistant/Relapsed DLBCL

Author

Visani, Giuseppe, primary, Guidi, Stefano, additional, Scalzulli, Potito, additional, Olivieri, Attilio, additional, Angelucci, Emanuele, additional, Capria, Savenia, additional, Patriarca, Francesca, additional, Castagnari, Barbara, additional, Angrilli, Francesco, additional, Vallisa, Daniele, additional, Musuraca, Gerardo, additional, Mengarelli, Andrea, additional, Galieni, Piero, additional, Gaudio, Francesco, additional, Tosi, Patrizia, additional, Zinzani, Pierluigi, additional, Bosi, Alberto, additional, Baronciani, Donatella, additional, Cascavilla, Nicola, additional, Guiducci, Barbara, additional, Clissa, Cristina, additional, Gabucci, Elisa, additional, Rocchi, Marco, additional, Loscocco, Federica, additional, and Isidori, Alessandro, additional

Published
2016
Full Text
View/download PDF

44. Dust measurements in the coma of comet 67P/Churyumov-Gerasimenko inbound to the Sun

Author

Rotundi, Alessandra, Sierks, Holger, Della Corte, Vincenzo, Fulle, Marco, Gutierrez, Pedro J., Lara, Luisa, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Koschny, Detlef, Rickman, Hans, Keller, Horst Uwe, Lopez-Moreno, Jose J., Accolla, Mario, Agarwal, Jessica, A'Hearn, Michael F., Altobelli, Nicolas, Angrilli, Francesco, Barucci, M. Antonietta, Bertaux, Jean-Loup, Bertini, Ivano, Bodewits, Dennis, Bussoletti, Ezio, Colangeli, Luigi, Cosi, Massimo, Cremonese, Gabriele, Crifo, Jean-Francois, Da Deppo, Vania, Davidsson, Björn, Debei, Stefano, De Cecco, Mariolino, Esposito, Francesca, Ferrari, Marco, Fornasier, Sonia, Giovane, Frank, Gustafson, Bo, Green, Simon F., Groussin, Olivier, Gruen, Eberhard, Guettler, Carsten, Herranz, Miguel L., Hviid, Stubbe F., Ip, Wing, Ivanovski, Stavro, Jernimo, Jose M., Jorda, Laurent, Knollenberg, Joerg, Kramm, Rainer, Kuehrt, Ekkehard, Kueppers, Michael, Lazzarin, Monica, Leese, Mark R., Lopez-Jimenez, Antonio C., Lucarelli, Francesca, Lowry, Stephen C., Marzari, Francesco, Epifani, Elena Mazzotta, McDonnell, J. Anthony M., Mennella, Vito, Michalik, Harald, Molina, Antonio, Morales, Rafael, Moreno, Fernando, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Ortiz, Jose L., Palomba, Ernesto, Palumbo, Pasquale, Perrin, Jean-Marie, Rodriguez, Julio, Sabau, Lola, Snodgrass, Colin, Sordini, Roberto, Thomas, Nicolas, Tubiana, Cecilia, Vincent, Jean-Baptiste, Weissman, Paul, Wenzel, Klaus-Peter, Zakharov, Vladimir, Zarnecki, John C., Rotundi, Alessandra, Sierks, Holger, Della Corte, Vincenzo, Fulle, Marco, Gutierrez, Pedro J., Lara, Luisa, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Koschny, Detlef, Rickman, Hans, Keller, Horst Uwe, Lopez-Moreno, Jose J., Accolla, Mario, Agarwal, Jessica, A'Hearn, Michael F., Altobelli, Nicolas, Angrilli, Francesco, Barucci, M. Antonietta, Bertaux, Jean-Loup, Bertini, Ivano, Bodewits, Dennis, Bussoletti, Ezio, Colangeli, Luigi, Cosi, Massimo, Cremonese, Gabriele, Crifo, Jean-Francois, Da Deppo, Vania, Davidsson, Björn, Debei, Stefano, De Cecco, Mariolino, Esposito, Francesca, Ferrari, Marco, Fornasier, Sonia, Giovane, Frank, Gustafson, Bo, Green, Simon F., Groussin, Olivier, Gruen, Eberhard, Guettler, Carsten, Herranz, Miguel L., Hviid, Stubbe F., Ip, Wing, Ivanovski, Stavro, Jernimo, Jose M., Jorda, Laurent, Knollenberg, Joerg, Kramm, Rainer, Kuehrt, Ekkehard, Kueppers, Michael, Lazzarin, Monica, Leese, Mark R., Lopez-Jimenez, Antonio C., Lucarelli, Francesca, Lowry, Stephen C., Marzari, Francesco, Epifani, Elena Mazzotta, McDonnell, J. Anthony M., Mennella, Vito, Michalik, Harald, Molina, Antonio, Morales, Rafael, Moreno, Fernando, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Ortiz, Jose L., Palomba, Ernesto, Palumbo, Pasquale, Perrin, Jean-Marie, Rodriguez, Julio, Sabau, Lola, Snodgrass, Colin, Sordini, Roberto, Thomas, Nicolas, Tubiana, Cecilia, Vincent, Jean-Baptiste, Weissman, Paul, Wenzel, Klaus-Peter, Zakharov, Vladimir, and Zarnecki, John C.

Abstract

Critical measurements for understanding accretion and the dust/gas ratio in the solar nebula, where planets were forming 4.5 billion years ago, are being obtained by the GIADA (Grain Impact Analyser and Dust Accumulator) experiment on the European Space Agency's Rosetta spacecraft orbiting comet 67P/Churyumov-Gerasimenko. Between 3.6 and 3.4 astronomical units inbound, GIADA and OSIRIS (Optical, Spectroscopic, and Infrared Remote Imaging System) detected 35 outflowing grains of mass 10(-10) to 10(-7) kilograms, and 48 grains of mass 10(-5) to 10(-2) kilograms, respectively. Combined with gas data from the MIRO (Microwave Instrument for the Rosetta Orbiter) and ROSINA (Rosetta Orbiter Spectrometer for Ion and Neutral Analysis) instruments, we find a dust/gas mass ratio of 4 +/- 2 averaged over the sunlit nucleus surface. A cloud of larger grains also encircles the nucleus in bound orbits from the previous perihelion. The largest orbiting clumps are meter-sized, confirming the dust/gas ratio of 3 inferred at perihelion from models of dust comae and trails.

Published
2015
Full Text
View/download PDF

45. On the nucleus structure and activity of comet 67P/Churyumov-Gerasimenko

Author

Sierks, Holger, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Koschny, Detlef, Rickman, Hans, Keller, Horst Uwe, Agarwal, Jessica, A'Hearn, Michael F., Angrilli, Francesco, Auger, Anne-Therese, Barucci, M. Antonella, Bertaux, Jean-Loup, Bertini, Ivano, Besse, Sebastien, Bodewits, Dennis, Capanna, Claire, Cremonese, Gabriele, Da Deppo, Vania, Davidsson, Bjoern, Debei, Stefano, De Cecco, Mariolino, Ferri, Francesca, Fornasier, Sonia, Fulle, Marco, Gaskell, Robert, Giacomini, Lorenza, Groussin, Olivier, Gutierrez-Marques, Pablo, Gutiuerrez, Pedro J., Guettler, Carsten, Hoekzema, Nick, Hviid, Stubbe F., Ip, Wing-Huen, Jorda, Laurent, Knollenberg, Joerg, Kovacs, Gabor, Kramm, J. Rainer, Kuehrt, Ekkehard, Kueppers, Michael, La Forgia, Fiorangela, Lara, Luisa M., Lazzarin, Monica, Leyrat, Cedric, Moreno, Jose J. Lopez, Magrin, Sara, Marchi, Simone, Marzari, Francesco, Massironi, Matteo, Michalik, Harald, Moissl, Richard, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Pajola, Maurizio, Pertile, Marco, Preusker, Frank, Sabau, Lola, Scholten, Frank, Snodgrass, Colin, Thomas, Nicolas, Tubiana, Cecilia, Vincent, Jean-Baptiste, Wenzel, Klaus-Peter, Zaccariotto, Mirco, Paetzold, Martin, Sierks, Holger, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Koschny, Detlef, Rickman, Hans, Keller, Horst Uwe, Agarwal, Jessica, A'Hearn, Michael F., Angrilli, Francesco, Auger, Anne-Therese, Barucci, M. Antonella, Bertaux, Jean-Loup, Bertini, Ivano, Besse, Sebastien, Bodewits, Dennis, Capanna, Claire, Cremonese, Gabriele, Da Deppo, Vania, Davidsson, Bjoern, Debei, Stefano, De Cecco, Mariolino, Ferri, Francesca, Fornasier, Sonia, Fulle, Marco, Gaskell, Robert, Giacomini, Lorenza, Groussin, Olivier, Gutierrez-Marques, Pablo, Gutiuerrez, Pedro J., Guettler, Carsten, Hoekzema, Nick, Hviid, Stubbe F., Ip, Wing-Huen, Jorda, Laurent, Knollenberg, Joerg, Kovacs, Gabor, Kramm, J. Rainer, Kuehrt, Ekkehard, Kueppers, Michael, La Forgia, Fiorangela, Lara, Luisa M., Lazzarin, Monica, Leyrat, Cedric, Moreno, Jose J. Lopez, Magrin, Sara, Marchi, Simone, Marzari, Francesco, Massironi, Matteo, Michalik, Harald, Moissl, Richard, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Pajola, Maurizio, Pertile, Marco, Preusker, Frank, Sabau, Lola, Scholten, Frank, Snodgrass, Colin, Thomas, Nicolas, Tubiana, Cecilia, Vincent, Jean-Baptiste, Wenzel, Klaus-Peter, Zaccariotto, Mirco, and Paetzold, Martin

Abstract

Images from the OSIRIS scientific imaging system onboard Rosetta show that the nucleus of 67P/Churyumov-Gerasimenko consists of two lobes connected by a short neck. The nucleus has a bulk density less than half that of water. Activity at a distance from the Sun of >3 astronomical units is predominantly from the neck, where jets have been seen consistently. The nucleus rotates about the principal axis of momentum. The surface morphology suggests that the removal of larger volumes of material, possibly via explosive release of subsurface pressure or via creation of overhangs by sublimation, may be a major mass loss process. The shape raises the question of whether the two lobes represent a contact binary formed 4.5 billion years ago, or a single body where a gap has evolved via mass loss.

Published
2015
Full Text
View/download PDF

46. The morphological diversity of comet 67P/Churyumov-Gerasimenko

Author

Thomas, Nicolas, Sierks, Holger, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Rickman, Hans, Koschny, Detlef, Keller, Horst Uwe, Agarwal, Jessica, A'Hearn, Michael F., Angrilli, Francesco, Auger, Anne-Therese, Barucci, M. Antonella, Bertaux, Jean-Loup, Bertini, Ivano, Besse, Sebastien, Bodewits, Dennis, Cremonese, Gabriele, Da Deppo, Vania, Davidsson, Björn, De Cecco, Mariolino, Debei, Stefano, El-Maarry, Mohamed Ramy, Ferri, Francesca, Fornasier, Sonia, Fulle, Marco, Giacomini, Lorenza, Groussin, Olivier, Gutierrez, Pedro J., Guettler, Carsten, Hviid, Stubbe F., Ip, Wing-Huen, Jorda, Laurent, Knollenberg, Joerg, Kramm, J. -Rainer, Kuehrt, Ekkehard, Kueppers, Michael, La Forgia, Fiorangela, Lara, Luisa M., Lazzarin, Monica, Moreno, Jose J. Lopez, Magrin, Sara, Marchi, Simone, Marzari, Francesco, Massironi, Matteo, Michalik, Harald, Moissl, Richard, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Pajola, Maurizio, Pommerol, Antoine, Preusker, Frank, Sabau, Lola, Scholten, Frank, Snodgrass, Colin, Tubiana, Cecilia, Vincent, Jean-Baptiste, Wenzel, Klaus-Peter, Thomas, Nicolas, Sierks, Holger, Barbieri, Cesare, Lamy, Philippe L., Rodrigo, Rafael, Rickman, Hans, Koschny, Detlef, Keller, Horst Uwe, Agarwal, Jessica, A'Hearn, Michael F., Angrilli, Francesco, Auger, Anne-Therese, Barucci, M. Antonella, Bertaux, Jean-Loup, Bertini, Ivano, Besse, Sebastien, Bodewits, Dennis, Cremonese, Gabriele, Da Deppo, Vania, Davidsson, Björn, De Cecco, Mariolino, Debei, Stefano, El-Maarry, Mohamed Ramy, Ferri, Francesca, Fornasier, Sonia, Fulle, Marco, Giacomini, Lorenza, Groussin, Olivier, Gutierrez, Pedro J., Guettler, Carsten, Hviid, Stubbe F., Ip, Wing-Huen, Jorda, Laurent, Knollenberg, Joerg, Kramm, J. -Rainer, Kuehrt, Ekkehard, Kueppers, Michael, La Forgia, Fiorangela, Lara, Luisa M., Lazzarin, Monica, Moreno, Jose J. Lopez, Magrin, Sara, Marchi, Simone, Marzari, Francesco, Massironi, Matteo, Michalik, Harald, Moissl, Richard, Mottola, Stefano, Naletto, Giampiero, Oklay, Nilda, Pajola, Maurizio, Pommerol, Antoine, Preusker, Frank, Sabau, Lola, Scholten, Frank, Snodgrass, Colin, Tubiana, Cecilia, Vincent, Jean-Baptiste, and Wenzel, Klaus-Peter

Abstract

Images of comet 67P/Churyumov-Gerasimenko acquired by the OSIRIS (Optical, Spectroscopic and Infrared Remote Imaging System) imaging system onboard the European Space Agency's Rosetta spacecraft at scales of better than 0.8 meter per pixel show a wide variety of different structures and textures. The data show the importance of airfall, surface dust transport, mass wasting, and insolation weathering for cometary surface evolution, and they offer some support for subsurface fluidization models and mass loss through the ejection of large chunks of material.

Published
2015
Full Text
View/download PDF

48. Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study

Author

Pinto, Antonello, primary, Pavone, Vincenzo, additional, Angrilli, Francesco, additional, Saggese, Mariangela, additional, Crisci, Stefania, additional, Patti, Caterina, additional, Zinzani, Pier Luigi, additional, D'Arco, Alfonso Maria, additional, Cavalieri, Elena, additional, Guarini, Attilio, additional, Spina, Michele, additional, Carlino, Daniela, additional, Falorio, Simona, additional, Morelli, Emanuela, additional, Arcamone, Manuela, additional, Frigeri, Ferdinando, additional, De Chiara, Annarosaria, additional, De Filippi, Rosaria, additional, and Corazzelli, Gaetano, additional

Published
2015
Full Text
View/download PDF

49. Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Author

Isidori, Alessandro, primary, Guidi, Stefano, additional, Scalzulli, Potito Rosario, additional, Olivieri, Attilio, additional, Angelucci, Emanuele, additional, Capria, Saveria, additional, Patriarca, Francesca, additional, Castagnari, Barbara, additional, Angrilli, Francesco, additional, Vallisa, Daniele, additional, Musuraca, Gerardo, additional, Mengarelli, Andrea, additional, Galieni, Piero, additional, Francesco, Gaudio, additional, Tosi, Patrizia, additional, Zinzani, Pier Luigi, additional, Bosi, Alberto, additional, Baronciani, Donatella, additional, Cascavilla, Nicola, additional, Guiducci, Barbara, additional, Clissa, Cristina, additional, Gabucci, Elisa, additional, Rocchi, Marco, additional, Loscocco, Federica, additional, and Visani, Giuseppe, additional

Published
2015
Full Text
View/download PDF

50. A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients

Author

Gentile, Massimo, primary, Shanafelt, Tait D., additional, Cutrona, Giovanna, additional, Molica, Stefano, additional, Tripepi, Giovanni, additional, Alvarez, Isabel, additional, Mauro, Francesca Romana, additional, Di Renzo, Nicola, additional, Di Raimondo, Francesco, additional, Vincelli, Iolanda D., additional, Todoerti, Katia, additional, Matis, Serena, additional, Musolino, Caterina, additional, Fabris, Sonia, additional, Vigna, Ernesto, additional, Levato, Luciano, additional, Zupo, Simona, additional, Angrilli, Francesco, additional, Consoli, Ugo, additional, Festini, Gianluca, additional, Longo, Giuseppe, additional, Cortelezzi, Agostino, additional, Arcari, Annalisa, additional, Federico, Massimo, additional, Mannina, Donato, additional, Recchia, Anna Grazia, additional, Kay, Neil E., additional, Ferrarini, Manlio, additional, Neri, Antonino, additional, and Morabito, Fortunato, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results